Stay updated with breaking news from Efficacy Signals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators of an ongoing phase 1a/1b multicohort trial are studying whether addition of adaptive immune activators increases the benefit derived from anti–PD-1 antibodies in multiple tumor types.
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute...
Dr. kory, it certainly feels that way. tell me about the safety and the effectiveness of things like hydroxychloroquine, i'veer member tin and there was also another one. >> all three medications have been around for decades. they have unparalleled safety profiles. and the efficacy signals around them are now inarguable, unquestionable. there's such -- they sit atop large evidence bases. and i have to tell you, myself and my organization, we've spent the whole pandemic trying to disseminate the evidence of efficacy from doctors to patients to people, and they are listening. and my organization...
Dr. kory, it certainly feels that way. tell me about the safety and the effectiveness of things like hydroxychloroquine, i'veer member tin and there was also another one. >> all three medications have been around for decades. they have unparalleled safety profiles. and the efficacy signals around them are now inarguable, unquestionable. there's such -- they sit atop large evidence bases. and i have to tell you, myself and my organization, we've spent the whole pandemic trying to disseminate the evidence of efficacy from doctors to patients to people, and they are listening. and my organization...